Drug profile · INN
rivaroxaban
APO-RIVAROXABAN
rivaroxaban (APO-RIVAROXABAN) is a coagulation factor x inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — rivaroxaban
- US status
- approved
- Class
- Blood and blood forming organs (B01)
- Route
- ORAL
- Patents
- 0
- Programs
- 24
- Data quality
- 0.89
Quick answer
rivaroxaban (APO-RIVAROXABAN) is a coagulation factor x inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Coagulation factor X inhibitor
Primary target: Coagulation factor X
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rivaroxaban?
rivaroxaban (APO-RIVAROXABAN) is a coagulation factor x inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rivaroxaban?
APO-RIVAROXABAN is a marketed brand name for rivaroxaban. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rivaroxaban?
rivaroxaban has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.